AnaptysBio - Home
About
Overview
Strategy
Management
Board of Directors
Research and Development Committee
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Imsidolimab
Rosnilimab
ANB032
Partnerships
Investors / News
Overview
News
Events
Goverance
Stock Information
Analyst Coverage
SEC Filings
FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Toggle
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
November 29, 2021
AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
November 15, 2021
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
About
Technology
Pipeline
Investors
Careers
